ArticleAmerican journal of ophthalmology case reports2024
Clinico-pathologic correlation in ocular sarcoidosis.
Article in American journal of ophthalmology case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Pediatric peripapillary choroidal neovascularization secondary to ocular sarcoidosis: a long-term follow-up case.BMC ophthalmology · 2025Article
- Development and validation of potential molecular subtypes and signatures of ocular sarcoidosis based on autophagy-related gene analysis.Open medicine (Warsaw, Poland) · 2025Article
- Ocular Sarcoidosis: Contemporary Insights and Future Directions.Romanian journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Purpose: This case describes the unique course and management of a patient with progressive, refractory multi-system sarcoidosis that initially presented with ocular and dermatologic findings. Observations: A 47-year-old male presented with acute anterior uveitis and was found to have simultaneous inflammation of his skin at a tattoo site. Diagnosis of ocular sarcoidosis was confirmed through skin biopsy. Treatment with prednisone and adalimumab was initiated. Despite systemic immunosuppression and control of systemic inflammation, the patient had refractory ocular disease and developed bilateral disc edema and peripapillary choroidal neovascular membranes with subretinal fluid, so oral methotrexate and as-needed intravitreal bevacizumab injections were added. However, the patient manifested hepatic and worsening pulmonary involvement, prompting discontinuation of both methotrexate and adalimumab. Biopsy of the liver later confirmed hepatic sarcoidosis over drug-induced liver injury. Out of precaution for methotrexate-associated hepatic toxicity, mycophenolate mofetil was initiated instead, which then led to resolution of the subretinal fluid and disease quiescence. Conclusions and Importance: This case offers insight into the varying presentation and recalcitrant course of sarcoidosis. It documents a clinicopathologic case with unique initial presentation with biopsies of multiple organs, escalation of therapy with several immunomodulatory agents, and multidisciplinary collaboration to achieve ocular and systemic quiescence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.